Frontier Biologics

Executive Summary

Frontier Biologics is a Cambridge, MA-based biotechnology company advancing regenerative medicine through its proprietary Evexcell™ processing platform. The platform converts perinatal tissues into acellular biologic products rich in extracellular vesicles, proteins, and growth factors, offering a novel approach to tissue repair without the risks associated with cell-based therapies. Founded in 2016, the company is initially targeting indications with high unmet need, leveraging the immunomodulatory and pro-regenerative properties of its products. While still in early-stage development, Frontier's technology differentiates itself by providing a standardized, scalable, and off-the-shelf biologic that avoids the regulatory and manufacturing complexities of living cell therapies. The company's focus on perinatal-derived materials positions it within a growing field of regenerative biologics, though clinical validation and funding details remain limited.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation for lead product candidate40% success
• Q2 2026FDA Pre-IND meeting or IND clearance60% success
• TBDStrategic partnership or licensing deal for Evexcell platform50% success